Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer
Open Access
- 2 February 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in Molecular Cancer
- Vol. 16 (1), 1-9
- https://doi.org/10.1186/s12943-017-0608-9
Abstract
Colorectal cancer is third most common malignancy and is the second most common cause of cancer-related death. The MUC1 heterodimeric protein is aberrantly overexpressed in colorectal cancer and has been linked to poor outcomes in this disease. Here, we investigate the effects of the MUC1-C subunit inhibitor (GO-203), which disrupts MUC1-C homo-oligomerization, on human colorectal cancer cells. TIGAR mRNA level was determined using qRT-PCR. Western blotting was used to measure TIGAR protein level and AKT-mTOR-S6K1 pathways. Reactive oxygen species and apoptosis were measured by flow cytometry. Effect of MUC1-C peptide, GO-203 was studied on colorectal xenograft tumors. Immunohistochemistry was utilized for TIGAR staining. Treatment of MUC1-overexpressing SKCO-1 and Colo-205 colon cancer cells with GO-203 was associated with downregulation of the TP53-inducible glycolysis and apoptosis regulator (TIGAR) protein. TIGAR promotes the shunting of glycolytic intermediates into the pentose phosphate pathway and thus is of importance for maintaining redox balance. We show that GO-203-induced suppression of TIGAR is mediated by inhibition of AKT and the downstream mTOR pathway. The results also demonstrate that targeting MUC1-C blocks eIF4A cap-dependent translation of TIGAR. In concert with these results, GO-203-induced suppression of TIGAR was associated with decreases in GSH levels. GO-203 treatment also resulted in increases in reactive oxygen species (ROS) and loss of mitochondrial transmembrane potential. Consistent with these results, GO-203 inhibited the growth of colon cancer cells in vitro and as xenografts in nude mice. Inhibition of MUC1-C also downregulated TIGAR expression in xenograft tissues. These findings indicate that MUC1-C is a potential target for the treatment of colorectal cancer. Colorectal cancer patients who overexpress MUC1-C may be candidates for treatment with the MUC1-C inhibitor alone or in combination therapy with other agents.Keywords
Funding Information
- National Institutes of Health (CA97098, CA166480)
This publication has 45 references indexed in Scilit:
- Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cellsNature Communications, 2013
- TIGAR Is Required for Efficient Intestinal Regeneration and TumorigenesisDevelopmental Cell, 2013
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- Maintenance of adenomatous polyposis coli ( APC )-mutant colorectal cancer is dependent on Wnt/β-catenin signalingProceedings of the National Academy of Sciences of the United States of America, 2011
- Molecular mechanisms of mTOR-mediated translational controlNature Reviews Molecular Cell Biology, 2009
- Constitutive NF-κB Activation in Colorectal Carcinoma Plays a Key Role in Angiogenesis, Promoting Tumor GrowthClinical Cancer Research, 2009
- Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological TargetsCell, 2009
- MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer modelVaccine, 2007
- S6K1- and ßTRCP-Mediated Degradation of PDCD4 Promotes Protein Translation and Cell GrowthScience, 2006
- Prognostic significance of mucins in colorectal cancer with different DNA mismatch-repair statusJournal of Clinical Pathology, 2006